NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Lori Brumat: Why Women’s Health Should Matter to Everyone Right Now
Lori Brumat/LinkedIn
Mar 21, 2026, 19:13

Lori Brumat: Why Women’s Health Should Matter to Everyone Right Now

Lori Brumat, Co-Founder and  Strategic Advisor at Advocato, shared a post on LinkedIn:

“I am heading to the Women’s Health Executive and Research Summit (HERS) in San Diego next Monday, and I want to tell you why women’s health is one of the issues that should matter most to you right now.

Women are 51% of the population.

They make 80% of healthcare decisions, including for your own kids.

They are your mothers, daughters, partners, and colleagues.

And yet drugs for them are still dosed based on male biology, conditions like endometriosis take seven years to diagnose, and the market serving their health needs remains one of the most underfunded in existence.

This is not new. Women’s health has been chronically neglected for decades.

But in the past three months alone, over $3 billion in federal grants supporting women across health, research, and economic security have been cancelled in the United States, on the grounds that focusing on women is ‘discriminatory.’

That public research is the pipeline that feeds private innovation: the science that becomes the startups, the data that attracts investors, the evidence that gets drugs approved.

When you cut it, the whole ecosystem feels it, years down the line.

Which is exactly why what is happening at HERS next week matters.

And if the moral case does not move you: women’s health is a market worth hundreds of billions, barely touched, with $1 trillion in productivity waiting to be unlocked the minute women get better treatment.

Here are five conversations I will not be missing next week:
  • Megan Scheffel from SVB will be making the financial case for why women’s health was never a niche market to begin with.
  • Oriana Papin-Zoghbi of AOA Dx has years of exit data to back that up: over $100 billion in realized value that most investors simply were not looking for.
  • Sue McKinney of Altin Biosciences will be telling one of the most original stories around: how you navigate the FDA’s botanical drug pathway to bring a non-hormonal treatment for uterine fibroids to market. A condition affecting 26 million women in the US, whose current treatments are hormonal, invasive, and often fertility-ending.
  • Nisha Perez from HotSpot Therapeutics, Inc. will be presenting cautionary tales of what actually happens to women when drugs are developed without adequately studying female biology.
  • Sophie Zaaijer from University of California, Riverside will be challenging something most people assumed was progress: why simply counting women in clinical trials was never remotely enough.

I listen to founders, investors, and the people help them tell the stories that move the needle.

I will be posting from the summit. Follow along if this issue matters to you.”

Lori Brumat

Stay updated on all scientific advances in the field of fertility with Fertility News.

biology Female Biology Fertility Fertility News fertility-ending HERS hormonal HotSpot Therapeutics Lori Brumat Megan Scheffel Nisha Perez Oriana Papin-Zoghbi Sophie Zaaijer Sue McKinney Uterine Fibroids Women's Health Executive and Research Summit
NewsFeed